Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-0500
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report ; volume:7 ; number:1 ; day:2 ; month:9 ; year:2014 ; pages:1-4 ; date:12.2014
BMC Research Notes / Biomed Central; 7, Heft 1 (2.9.2014), 1-4, 12.2014
- Creator
-
Bearz, Alessandra
Santarossa, Sandra
Manfrè, Antonio
Beltrame, Giorgio
Urbani, Martina
Sartor, Ivana
Da Ros, Valentina
Tirelli, Umberto
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1756-0500-7-589
- URN
-
urn:nbn:de:101:1-2019090423090817398610
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bearz, Alessandra
- Santarossa, Sandra
- Manfrè, Antonio
- Beltrame, Giorgio
- Urbani, Martina
- Sartor, Ivana
- Da Ros, Valentina
- Tirelli, Umberto
- SpringerLink (Online service)
Other Objects (12)
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
Alecensa bei ALK-positivem NSCLC
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
AGE/RAGE axis regulates reversible transition to quiescent states of ALK-rearranged NSCLC and pancreatic cancer cells in monolayer cultures
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
Alecensa bei ALK-positivem NSCLC
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
AGE/RAGE axis regulates reversible transition to quiescent states of ALK-rearranged NSCLC and pancreatic cancer cells in monolayer cultures
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
Alecensa bei ALK-positivem NSCLC
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
AGE/RAGE axis regulates reversible transition to quiescent states of ALK-rearranged NSCLC and pancreatic cancer cells in monolayer cultures
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC